# Phase 3 Neoplasm Metastasis trials recruiting: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials in phase 3 for Neoplasm Metastasis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Neoplasm Metastasis trials: 41 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/neoplasm-metastasis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 13, 2026 | NCT07869836 | BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial... | SystImmune Inc. | Phase 3 | Recruiting | Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC), Bladder (Urothelial, Transitional... | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869836) |
| September 11, 2026 | NCT07815834 | FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled... | Fudan University | Phase 3 | Recruiting | Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy... | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815834) |
| September 3, 2026 | NCT07802626 | Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing | SWOG Cancer Research Network | Phase 3 | Not yet recruiting | HR Positive/HER-2 Negative Breast Cancer | 1,084 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802626) |
| August 7, 2026 | NCT07751133 | Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer | University College, London | Phase 3 | Recruiting | Prostate Cancer, mHSPC, mCRPC | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751133) |
| July 20, 2026 | NCT07715396 | Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden | AIO-Studien-gGmbH | Phase 3 | Not yet recruiting | Non-small Cell Lung Cancer Metastatic | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715396) |
| June 15, 2026 | NCT07647328 | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer | AstraZeneca | Phase 3 | Recruiting | ER-Positive HER2-Negative Breast Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647328) |
| June 2, 2026 | NCT07621601 | A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | Hansoh BioMedical R&D Company | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 494 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621601) |
| May 1, 2026 | NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Immuneering Corporation | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562152) |
| April 17, 2026 | NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | Tongji Hospital | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Metastases | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537946) |
| December 15, 2025 | NCT07281833 | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine... | Women's Cancer Study Group GmbH | Phase 3 | Recruiting | Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281833) |
| October 30, 2025 | NCT07222800 | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With... | Pfizer | Phase 3 | Recruiting | Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System... | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222800) |
| October 30, 2025 | NCT07222566 | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants... | Pfizer | Phase 3 | Recruiting | Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma... | 1,410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222566) |
| October 28, 2025 | NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated... | mAbxience Research S.L. | Phase 3 | Recruiting | Advanced (Unresectable or Metastatic) Melanoma | 632 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221734) |
| October 20, 2025 | NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Eli Lilly and Company | Phase 3 | Recruiting | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218380) |
| October 9, 2025 | NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C)... | Eli Lilly and Company | Phase 3 | Recruiting | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis | 1,630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213804) |
| October 3, 2025 | NCT07205822 | A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | AstraZeneca | Phase 3 | Recruiting | Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07205822) |
| September 15, 2025 | NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic... | Eli Lilly and Company | Phase 3 | Recruiting | Breast Neoplasms, Neoplasm Metastasis | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07174336) |
| June 30, 2025 | NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | AstraZeneca | Phase 3 | Recruiting | Endometrial Cancer, Malignant Solid Tumour | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044336) |
| May 7, 2025 | NCT06961188 | Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key... | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With... | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961188) |
| March 27, 2025 | NCT06897644 | Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With... | Gruppo Oncologico del Nord-Ovest | Phase 3 | Recruiting | Pancreatic Adenocarcinoma Advanced or Metastatic | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06897644) |
| January 3, 2025 | NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Celcuity Inc | Phase 3 | Recruiting | Breast Cancer | 1,180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06757634) |
| November 8, 2024 | NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With... | Tempest Therapeutics | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 740 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06680258) |
| April 30, 2024 | NCT06391242 | Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases | Canadian Cancer Trials Group | Phase 3 | Recruiting | Cancer Metastatic | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06391242) |
| April 3, 2024 | NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | Centre Leon Berard | Phase 3 | Recruiting | Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06346197) |
| February 23, 2024 | NCT06275958 | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer | Leiden University Medical Center | Phase 3 | Recruiting | Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy | 587 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06275958) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 4 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| Sun Yat-sen University | 2 |
| Fudan University | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| Gruppo Oncologico del Nord-Ovest | 1 |
| UNICANCER | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Canadian Cancer Trials Group | 1 |
| AIO-Studien-gGmbH | 1 |
| Women's Cancer Study Group GmbH | 1 |
| SystImmune Inc. | 1 |
| Institut Curie | 1 |
| BriaCell Therapeutics Corporation | 1 |
| Stanford University | 1 |
| Immuneering Corporation | 1 |
| NovoCure GmbH | 1 |
| Servier Bio-Innovation LLC | 1 |
| [Changchun GeneScience Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd) | 1 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 1 |
| Tempest Therapeutics | 1 |
| Centre Leon Berard | 1 |
| Leiden University Medical Center | 1 |
| Celcuity Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| France | 20 |
| United States | 20 |
| Italy | 18 |
| Spain | 18 |
| China | 17 |
| Germany | 17 |
| Australia | 14 |
| Canada | 14 |
| Poland | 13 |
| South Korea | 13 |
| Taiwan | 13 |
| United Kingdom | 13 |
| Brazil | 12 |
| Belgium | 12 |
| Japan | 11 |
| Hungary | 10 |
| Czechia | 9 |
| Netherlands | 9 |
| Denmark | 8 |
| Turkey (Türkiye) | 8 |
| Argentina | 7 |
| Greece | 7 |
| Romania | 6 |
| Switzerland | 5 |
| Israel | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Artificial turf companies in the United States](https://specstream.ai/data/businesses/artificial-turf-companies/united-states)
- [Bankruptcy law firms in the United States](https://specstream.ai/data/businesses/bankruptcy-law-firms/united-states)
- [Cancer treatment centers in the United States](https://specstream.ai/data/businesses/cancer-treatment-centers/united-states)
- [Cooking schools in the United States](https://specstream.ai/data/businesses/cooking-schools/united-states)
